What pulled me back into the Nature Medicine paper twice was the curve. The open-label extension, the part of a Phase 2b trial nobody is supposed to fall in love with, was still climbing at week 56. Aleniglipron, Structure Therapeutics’ once-daily GLP-1 pill, had taken the 90 mg arm to 16.2 percent mean weight loss in interim data, and the slope had not bent. That number sits inside a story that has changed under everyone’s feet in the last six months.
For most of the GLP-1 era, “oral” was a polite way of saying “compromised.” Novo Nordisk’s Rybelsus, the oral semaglutide the FDA cleared back in 2019, is a peptide smuggled through the stomach lining with a permeation enhancer called SNAC and a long list of food-timing rules to make the absorption work. Anything bigger came from a needle. That sentence is no longer true. Oral Wegovy, the higher-dose obesity version of oral semaglutide, got its FDA nod in December 2025, and Eli Lilly’s orforglipron, the first non-peptide small-molecule oral GLP-1 to clear the agency, was approved on April 1, 2026. The oral GLP-1 race isn’t theoretical anymore.
Which is why aleniglipron lands differently than it would have a year ago. Structure Therapeutics, a South San Francisco biotech trading under the ticker GPCR, isn’t proving orals can work; Lilly already did that, with orforglipron landing at minus 12.4 percent placebo-adjusted weight loss at 72 weeks in its dedicated obesity program. Structure is making the case there is room for a third serious contender, and a Phase 2b readout this clean is how you make that case in front of investors and the FDA at the same time.
ACCESS, the 230-patient Phase 2b, randomized adults with overweight or obesity to three maintenance doses (45, 90, 120 mg) or placebo, ran 36 weeks of double-blind treatment, then rolled everyone into an open-label extension. Placebo-adjusted weight loss came in at 8.2, 9.8, and 11.3 percent across the three doses. For 36 weeks in a couple of hundred patients, those are respectable numbers, the kind that earn a Phase 3. They do not beat OASIS 1, where oral semaglutide at 50 mg pulled a 12.7-percentage-point separation from placebo at 68 weeks, and the honest cross-trial comparison isn’t yet possible because aleniglipron hasn’t been run that long. What aleniglipron did do is keep losing weight when the blinding came off, which is the part Julio Rosenstock, the longtime UT Southwestern endocrinology trialist who chairs the steering committee, leaned on in the company release. People were still on the slope when the lights came up.
Now, the biology of why a small molecule even gets to play in this league. Injectable GLP-1 drugs are synthetic peptides, basically longer-lived copies of the gut hormone your L-cells release after a meal. A small molecule has to clip onto the same receptor without looking anything like the natural ligand, because the GLP-1 receptor is a finicky G-protein coupled receptor with a deep peptide-binding pocket that historically did not want to be activated by anything you could swallow. Structure’s chemistry occupies that pocket, fires the same downstream signal, survives gastric acid, and does not need a chaperone molecule or a thirty-minute fasted sip-of-water ritual. That is pharmacology, not press-release flourish. It also means a manufacturing story closer to a normal small-molecule pill (cheaper API, no peptide synthesis) than to any injectable.
Two hundred and thirty patients is not a lot of patients. ACCESS was sized to find a signal, not to characterize who throws up and quits. Structure reported a 10.4 percent discontinuation rate, with most departures clustered in early titration, and the GI adverse events called “generally mild to moderate.” That is the standard sponsor sentence, and it has been the standard sentence for every GLP-1 in development. Phase 3 obesity trials, larger and more diverse and longer, almost always shake out more dropouts than Phase 2b runs do. Structure already knows that, which is why the Phase 3 starting dose is being set at 2.5 mg, a long way below the 45 mg low-maintenance arm in ACCESS. The company says the choice reflects both the trial data and an end-of-Phase-2 meeting with the FDA. The read underneath is the same either way: titration is the load-bearing safety problem they have already identified, and they are starting Phase 3 well below where ACCESS landed.
The other piece worth naming plainly is that this is a sponsor-designed, sponsor-funded trial with the company’s chief medical officer on the author list and a steering committee chair who runs the diabetes-trial circuit for a living. None of that is unusual in modern endocrinology research, and none of it makes the weight-loss numbers fake. But every reading of this drug, from here to approval, comes through a filter Structure built. The Nature paper is evidence. The “transform obesity treatment for patients worldwide” line in the company press release is marketing wearing a lab coat.
There is also a broader question that does not go away because the delivery vehicle got easier. GLP-1 receptor agonists work. We know this. What we still do not know are the things a 36-week Phase 2b cannot answer: durability of weight loss after people stop, behavior of the appetite circuitry under years of continuous receptor activation, long-tail signals that only surface in post-approval cohorts large enough and old enough to catch them. The injectable versions have been in widespread obesity use for a few years. The observational tail is still being written. If a daily pill gets approved at a price and manufacturing scale that flips GLP-1s from a specialty prescription into something closer to statins for metabolic disease, the timeline on every one of those open biological questions compresses by a lot. That is not a complaint about the chemistry. It is the stress test about to run on a much larger denominator than any trial will ever test.
What I would watch for is twofold. First, the Phase 3 readout, especially what the discontinuation curve looks like once people have been at maintenance dose for a full year. The FDA’s January 2025 draft guidance for obesity drugs leans on long maintenance-phase safety data and on how missing-data and dropouts are handled, which is the part of the curve that always quietly disqualifies a glossy Phase 2b. Second, whether the open-label extension keeps its no-plateau shape past the year mark, because durable loss is the story that separates the next-generation oral GLP-1s from the early Wegovy-era injectables that left a lot of people regaining weight within a year of stopping.
I came into this paper curious whether the chemistry could be made to work, and I am leaving convinced it can. That is not the same as being convinced the drug, the price tag, the marketing campaign, and the long observational tail will work for the people who eventually take it. Different questions. They get answered later, by different evidence, in trials that have not been run yet.
For now, the cleaner sentence than the one in the press release is this: a small American biotech in South San Francisco has put Phase 2b numbers on the board strong enough to take a swing in an oral GLP-1 race that, six months ago, did not yet have a finish line you could see. Whether aleniglipron is the molecule that catches orforglipron or oral Wegovy, or whatever Novo and Lilly are quietly chasing next, is a question Phase 3 owns. The race is on, and there is a third runner.